Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | AOC2 | O75106 | 1/20 | 0.36 |
| ▸ | FADS1 | O60427 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835998 | 0.81 | MAPK8 (0.56) | MAPK8SMN1; SMN2ALDH1A1ALPL | |
| SCHEMBL29500546 | 0.81 | MAPK8 (0.56) | MAPK8SMN1; SMN2ALDH1A1ALPL | |
| SCHEMBL16396814 | 0.80 | KEAP1 (0.53) | KEAP1ALDH1A1HDAC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL16236010 | 0.79 | MAPK8 (0.55) | MAPK8SMN1; SMN2ALDH1A1ALPL | |
| SCHEMBL837387 | 0.78 | P2RX7 (0.49) | ALDH1A1 | |
| SCHEMBL5192274 | 0.76 | KEAP1 (0.49) | KEAP1MAPK8ALDH1A1HDAC1HDAC3 | |
| SCHEMBL4405083 | 0.76 | PLA2G2A (0.51) | MAPK8 | |
| SCHEMBL28183476 | 0.75 | KEAP1 (0.43) | KEAP1SMN1; SMN2ALDH1A1HDAC1HDAC3 | |
| SCHEMBL16410276 | 0.74 | MTNR1A (0.50) | KEAP1ALDH1A1HDAC1HDAC2 | |
| Trifluoroacetic Acid SCHEMBL17824325 | 0.74 | MAPK8 (0.50) | MAPK8ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1427326-B1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1562600-A4 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | SUGEN INC (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1446117-A4 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| CN-101052394-A | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN INC (US) | 2007-10-10 | — | — | CN | disclosed |
| EP-1255752-B1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1301507-B1 | MANNICH BASE PRODRUGS OF 3 - (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | SUGEN INC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003035009-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-1301507-A2 | MANNICH BASE PRODRUGS OF 3 - (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN KINASES | Sugen, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020032204-A1 | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN INCORPORATED | 2002-03-14 | — | — | US | disclosed |
| WO-2001090068-A2 | MANNICH BASE PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AND THEIR USE A MODULATORS OF PROTEIN KINASES | SUGEN, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | KEAP1 1646/4885MAPK8 427/4885SMN1; SMN2 3803/4885 |
| US-20020032204-A1 | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | DMPK, PNKP, PLK2 | KEAP1 1690/4885MAPK8 428/4885SMN1; SMN2 2848/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | KEAP1 1219/4885MAPK8 353/4885SMN1; SMN2 3720/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | KEAP1 1205/4885MAPK8 348/4885SMN1; SMN2 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.